Moderna, Inc. (NASDAQ:MRNA) Holdings Decreased by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lessened its stake in Moderna, Inc. (NASDAQ:MRNA) by 1.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 41,598 shares of the company’s stock after selling 399 shares during the period. Mutual of America Capital Management LLC’s holdings in Moderna were worth $2,780,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Ashton Thomas Private Wealth LLC bought a new stake in shares of Moderna in the 2nd quarter worth $26,000. Family Firm Inc. acquired a new position in Moderna during the second quarter worth about $33,000. Bank & Trust Co bought a new stake in Moderna in the second quarter worth about $36,000. Hanseatic Management Services Inc. bought a new stake in Moderna in the second quarter worth about $48,000. Finally, Plato Investment Management Ltd boosted its position in shares of Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after purchasing an additional 288 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Trading Up 7.5 %

Moderna stock opened at $41.11 on Friday. Moderna, Inc. has a one year low of $35.80 and a one year high of $170.47. The company’s fifty day moving average price is $54.96 and its two-hundred day moving average price is $94.09. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The company has a market capitalization of $15.82 billion, a price-to-earnings ratio of -7.06 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the business earned ($1.39) EPS. The firm’s revenue was up 3.8% compared to the same quarter last year. On average, analysts forecast that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In related news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 13.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold a total of 2,930 shares of company stock worth $217,170 over the last 90 days. Insiders own 15.70% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on MRNA shares. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Friday, November 8th. Bank of America dropped their price target on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a report on Friday, September 13th. Wolfe Research started coverage on Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and set a $69.00 target price (down from $115.00) on shares of Moderna in a research report on Monday, November 18th. Finally, Sanford C. Bernstein assumed coverage on Moderna in a research report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Moderna has a consensus rating of “Hold” and an average price target of $84.00.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.